<DOC>
	<DOCNO>NCT02938520</DOCNO>
	<brief_summary>The First Long-Acting Injectable Regimen ( FLAIR ) study conduct establish human immunodeficiency virus type-1 ( HIV-1 ) infect adult participant whose virus virologically suppress integrase inhibitor single tablet regimen ( INI STR ) remain suppressed switch two-drug intramuscular ( IM ) long-acting ( LA ) regimen cabotegravir ( CAB ) rilpivirine ( RPV ) . In study , INI STR limit abacavir/dolutegravir/lamivudine ( ABC/DTG/3TC ) . FLAIR Phase 3 , multi-phase , randomize , open label , active-controlled , multicenter , parallel-group , non-inferiority study HIV-1 , anti-retroviral therapy ( ART ) -naïve adult participant . This study design demonstrate non-inferior antiviral activity switch two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 week ( Q4W : monthly ) compare remain ABC/DTG/3TC 48 week ( 4 week oral CAB + RPV , 44 week LA therapy ) . Participants HLA-B*5701 positive Screening may enroll study receive DTG plus non-abacavir contain dual nucleoside reverse transcriptase inhibitor ( NRTI ) regimen . Eligible particpants enroll Induction Phase study receive ABC/DTG/3TC 20 week ( Week [ -20 ] Day 1 ) . Participants HIV 1 ribose nucleic acid ( RNA ) &lt; 50 copy per milliliter ( c/mL ) Week ( -4 ) randomize ( 1:1 ) Maintenance Phase Day 1 either continue ABC/DTG/3TC discontinue ABC/DTG/3TC begin oral therapy CAB 30 mg + RPV 25 mg daily approximately 4 Weeks , follow monthly CAB LA + RPV LA injection visit Week 4b study completion withdrawal . At end Maintenance phase , eligible participant randomize continue ABC/DTG/3TC give option switch LA therapy Week 100 . Those participant ( HIV 1 RNA &lt; 50 c/mL Week 96 ) transition LA dosing , begin approximately 4 week oral CAB + RPV therapy Week 100 , receive first IM CAB LA + RPV LA injection Week 104b . Participants continue receive injection every 4 week Extension Phase CAB LA RPV LA either locally approve commercially available , participant long derive clinical benefit , participant meet protocol-defined reason discontinuation , development either CAB LA RPV LA terminate .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Tolerability Long-acting Intramuscular Cabotegravir Rilpivirine Maintenance Virologic Suppression Following Switch From Integrase Inhibitor HIV-1 Infected Therapy Naive Participants</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>HIV1 infect , ARTnaive men woman age 18 year great time signing informed consent . HIV1 infection document Screening plasma HIV1 RNA &gt; =1000 c/mL ; Antiretroviralnaive ( &lt; =10 day prior therapy antiretroviral agent follow diagnosis HIV1 infection ) . Any previous exposure HIV integrase inhibitor non nucleoside reverse transcriptase inhibitor exclusionary . Female Participants : A female participant eligible participate pregnant Screening first day Induction Phase ( confirm negative serum human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition : Nonreproductive potential define : Premenopausal females one following : Documented tubal ligation ; Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion ; Hysterectomy ; Documented Bilateral Oophorectomy ; Postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) 30 day prior first dose study medication , throughout study , least 30 day discontinuation oral study medication least 52 week discontinuation CAB LA RPV LA . The investigator responsible ensure participant understand properly use method contraception . All participant study counsel safer sexual practice include use benefit/risk effective barrier method ( e.g. , male condom ) risk HIV transmission uninfected partner . Capable give sign informed consent include compliance requirement restriction list consent form protocol . French participant eligible inclusion study either affiliate beneficiary social security category . Women pregnant , breastfeeding , plan become pregnant breastfeed study . Any evidence Screening active Centers Disease Prevention Control ( CDC ) Stage 3 disease , except cutaneous Kaposi 's sarcoma require systemic therapy historic current cluster differentiation4+ ( CD4+ ) cell count &lt; 200 cells/ cubic millimetre ( mm^3 ) exclusionary . Participants know moderate severe hepatic impairment . Any preexist physical mental condition ( include substance abuse disorder ) , opinion Investigator , may interfere participant 's ability comply dose schedule and/or protocol evaluation may compromise safety participant . Participants determine Investigator high risk seizure , include participant unstable poorly control seizure disorder . A participant prior history seizure may consider enrolment Investigator believe risk seizure recurrence low . All case prior seizure history discuss Medical Monitor prior enrolment . Participant , investigator 's judgment , pose significant suicide risk . Participant 's recent history suicidal behavior and/or suicidal ideation consider evaluate suicide risk . The participant tattoo dermatological condition overlie gluteus region may interfere interpretation injection site reaction . Evidence Hepatitis B virus ( HBV ) infection base result test Screening Hepatitis B surface antigen ( HBsAg ) , Hepatitis B core antibody ( anti HBc ) , Hepatitis B surface antibody ( antiHBs ) HBV dioxyribose nucleic acid ( DNA ) follow : Participants positive HBsAg exclude ; Participants negative antiHBs positive antiHBc ( negative HBsAg status ) positive HBV DNA exclude . Note : Participants positive antiHBc ( negative HBsAg status ) positive antiHBs ( past and/or current evidence ) immune HBV exclude . Asymptomatic individual chronic hepatitis C virus ( HCV ) infection exclude , however Investigators must carefully assess therapy specific HCV infection require ; participant anticipate require HCV treatment prior Week 48 Maintenance Phase must exclude . HCV treatment study may permit post Week 48 , follow consultation Medical Monitor . Participants HCV coinfection allow entry Phase 3 study : Liver enzymes meet entry criterion ; HCV Disease undergone appropriate workup , HCV advance , require treatment prior Week 48 visit . Additional information ( available ) participant HCV coinfection screen include result liver biopsy , fibroscan , ultrasound , fibrosis evaluation , history cirrhosis decompensated liver disease , prior treatment , timing/plan HCV treatment . In event recent biopsy image data available inconclusive , Fib4 score use verify eligibility . A Fib4 score &gt; 3.25 exclusionary ; Fib4 score 1.45 3.25 require Medical Monitor consultation . Fibrosis 4 Score Formula : ( Age x AST ) / ( Platelets x [ square root ALT ] ) . Unstable liver disease ( define following : presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone otherwise stable chronic liver disease per investigator assessment ) . History liver cirrhosis without hepatitis viral coinfection . Ongoing clinically relevant pancreatitis . All participant screen syphilis ( rapid plasma reagin [ RPR ] ) . Participants untreated syphilis infection , define positive RPR without clear documentation treatment , exclude . Participants positive RPR test treat may rescreened least 30 day completion antibiotic treatment syphilis . Ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous cell carcinoma , cervical , anal penile intraepithelial neoplasia ; localize malignancy require agreement investigator study Medical Monitor inclusion participant prior enrollment . Any condition , opinion Investigator , may interfere absorption , distribution , metabolism excretion drug render participant unable receive study medication . History presence allergy intolerance study drug component drug class . In addition , heparin use pharmacokinetic sampling ( PK ) sampling , participant history sensitivity heparin heparininduced thrombocytopenia must enrol . Current anticipate need chronic anticoagulation . Alanine aminotransferase ( ALT ) &gt; =3 time upper limit normal ( ULN ) . Clinically significant cardiovascular disease , define history/evidence congestive heart failure , symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PTCA ) clinically significant cardiac disease . Exposure experimental drug and/or experimental vaccine within 28 day 5 halflives test agent , twice duration biological effect test agent , whichever longer , prior first dose investigational product ( IP ) . Treatment follow agent within 28 day Screening : radiation therapy ; cytotoxic chemotherapeutic agent ; tuberculosis ( TB ) therapy , exception treatment latent TB isoniazid ; Immunomodulators alter immune response ( systemic corticosteroid , interleukin , interferon ) . Note : Participants use shortterm ( e.g . = &lt; 14 day ) systemic corticosteroid treatment , topical , inhaled intranasal corticosteroid eligible enrollment . Treatment HIV1 immunotherapeutic vaccine within 90 day Screening . Treatment agent , except recognize ART allow , documented activity HIV1 within 28 day first dose IP . Use medication associate Torsades de Pointes Any evidence primary resistance nonnuclease reverse transcriptase inhibitor ( NNRTIs ) ( except K103N allow ) , know resistance INIs historical resistance test result . Note : retests Screening genotype allow discretion study virologist . Participants HLAB*5701 positive unable use nuclease reverse transcriptase inhibitor ( NRTI ) backbone contain abacavir ( participant HLAB*5701 positive may enrol use NRTI backbone contain abacavir ; HLAB*5701 positive participant may exclude study local provision alternate NRTI backbone possible ) . Any verified Grade 4 laboratory abnormality . A single repeat test allow Screening Phase verify result . Any acute laboratory abnormality Screening , , opinion Investigator , would preclude participant 's participation study investigational compound . Participant estimate creatinine clearance &lt; 50 mL/min/1.73m^2 via Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) equation . Participants currently participate anticipate select interventional study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Antiretroviral agent</keyword>
	<keyword>Maintenance</keyword>
	<keyword>rilpivirine</keyword>
	<keyword>dolutegravir</keyword>
	<keyword>TMC278</keyword>
	<keyword>Triumeq</keyword>
	<keyword>non-nucleoside reverse transcriptase inhibitor</keyword>
	<keyword>monthly , every 4 week , daily</keyword>
	<keyword>GSK1265744</keyword>
	<keyword>CAB</keyword>
	<keyword>Tivicay</keyword>
	<keyword>Long-Acting Intramuscular rilpivirine</keyword>
	<keyword>lamivudine</keyword>
	<keyword>integrase inhibitor</keyword>
	<keyword>Long-Acting Intramuscular Cabotegravir</keyword>
	<keyword>ART naïve</keyword>
	<keyword>cabotegravir</keyword>
	<keyword>abacavir</keyword>
</DOC>